הבדלים בין גרסאות בדף "טבלאות רגישויות מבית החולים שערי צדק - תרביות דם - Shaare zedek medical center antibiotic sensitivity table - blood cultures"
מתוך ויקירפואה
שורה 233: | שורה 233: | ||
==טבלה 3: Enterobacteriaceae – antimicrobial susceptibilities (%) 2001-2008. Breakdown by source of patient== | ==טבלה 3: Enterobacteriaceae – antimicrobial susceptibilities (%) 2001-2008. Breakdown by source of patient== | ||
+ | |||
+ | ;מקרא: | ||
+ | *Amp-Ampicillin; | ||
+ | * Amk-Amikacin; | ||
+ | * Aug-Amoxycillin-clavulanate, | ||
+ | *Carbap-Carbapenems; | ||
+ | * Caz-Ceftazidime; | ||
+ | *Cef-Cefazolin; | ||
+ | * Chl-Chloramphenicol; | ||
+ | * Cip-Ciprofloxacin; | ||
+ | * Col-colistin (polymyxin-B); | ||
+ | * Cpm,-Cefepime, | ||
+ | * Cro-Ceftriaxone; | ||
+ | * Cxm-Cefuroxime; | ||
+ | * Ert-Ertapenem (since 2005); | ||
+ | * Gen-Gentamicin; | ||
+ | * Imp-Imipenem; | ||
+ | * Mez-Mezlocillin (up to mid-2006); | ||
+ | * Meth-Methicillin; Sep-Cotrimoxazole; | ||
+ | * Tob-Tobramycin; | ||
+ | * Tzp-Piperacillin-Tazobactam; | ||
+ | * Van-Vancomycin. | ||
+ | |||
{|dir="ltr" border="1" cellpadding="4" | {|dir="ltr" border="1" cellpadding="4" |
גרסה מ־14:28, 24 בספטמבר 2013
שם הספר: שימוש מושכל באנטיביוטיקה ונהלים למניעת זיהומים | |
---|---|
![]() | |
שם המחבר | פרופ' עמוס ינון, פרופ' יחיאל שלזינגר, דר' דוד רווה |
שם הפרק | טבלאות רגישויות מבית החולים שערי צדק - תרביות דם - Shaare zedek medical center antibiotic sensitivity table - blood cultures |
מוציא לאור | |
מועד הוצאה | תשע"א – 2010 |
מספר עמודים | 196 |
הקדשה | ספר זה מוקדש לפרופ' חיים הרשקו בהוקרה עמוקה |
טבלה 1. Number (%) of positive blood cultures/drawn cultures and rates of the most frequently isolated patient-specific isolated organisms/1000 admissions.
Variable/Year | 1990-2000[1] | 2001-2008[1] | ||
Annual Mean ± SD | 11year Total | Annual Mean ± SD | 8Year Total | |
Drawn blood cultures (BC) (n)[2] | 15,779 ± 4787 | 173,571 | 15,070 ± 1047 | 120,565 |
No. of true positive BC (n) | 1609 ± 524 | 17,703 | 1413 ± 125 | 11,308 |
Rate of true positive BC (%) | 10.2 ± 1.5 | 10.2 | 9.4 ± 1.1 | 9.4 |
No. of false positive BC (n) | NA[3] | NA | 1273 ± 132 | 10190 |
Rate of false positive BC (%) | NA | NA | 8.4±1.3 | 8.4 |
Rate/1000 admissions[4] | ||||
Enterobacteriaceae | 12.7±2 | 3394 | 13.2 | 4309 |
E. coli | 5.5±1 | 1494 | 6.4 | 2102 |
S. aureus | 4.7±0.9 | 1240 | 3.3 | 1238 |
K. pneumoniae | 3±0.8 | 779 | 3.3 | 1063 |
Enterococcus spp. | 2.3±0.7 | 631 | 2.9 | 939 |
P. aeruginosa | 1.9±0.5 | 488 | 1.5 | 505 |
S. pneumoniae | 1.7±0.4 | 447 | 2.1 | 681 |
Enterobacter spp. | 1.3±0.5 | 338 | 1.1 | 347 |
Acinetobacter spp. | 1±0.3 | 298 | 1.5 | 482 |
P. mirabilis | 1±0.2 | 260 | 1.4 | 449 |
טבלה 2: Enterobacteriaceae, producing Extended-Spectrum β-lactamases (ESBL) (n,%)2002-2008[5]
טבלה 2א: Collected in the Emergency Department
Year | All Enterobacteriaceae N=2330 (%) | E.coli N=1336 (%)
K.pneumoniae N=341 (%) |
P.mirabilis N=228 (%) | |
2002 | 42/286 (15) | 16/151 (11) | 13/54 (24) | 5/21 (24) |
2003 | 35/322 (11) | 15/191 (8) | 15/47 (32) | 4/28 (14) |
2004 | 41/307 (13) | 17/165 (10) | 8/40 (20) | 9/33 (27) |
2005 | 42/354 (11) | 20/218 (9) | 9/49 (18) | 11/38 (29) |
2006 | 61/319 (19) | 28/198 (14) | 17/37 (46) | 7/32 (22) |
2007 | 84/348 (24) | 46/190 (24) | 10/44 (23) | 19/33 (58) |
2008 | 79/357 (22) | 40/208 (19) | 18/59 (30) | 10/37 (27) |
Total | 393/2330 (16) | 185/1336 (14) | 92/341 (27) | 67/228 (29) |
טבלה 2ב': Collected from hospitalized patients
Year | All Enterobacteriaceae N=1562 (%) | E.coli N=347 (%) | K.pneumoniae N=495 (%) | P.mirabilis N=143 (%) |
2002 | 54/147 (37) | 7/35 (20) | 34/53 (64) | 2/6 (33) |
2003 | 62/213 (29) | 10/46 (22) | 22/55 (40) | 13/26 (50) |
2004 | 64/183 (35) | 11/48 (23) | 28/51 (55) | 10/18 (56) |
2005 | 93/234 (40) | 22/58 (38) | 35/68 (51) | 17/30 (57) |
2006 | 97/267 (36) | 13/54 (24) | 54/86 (63) | 15/29 (52) |
2007 | 58/244 (24) | 12/44 (27) | 35/99 (35) | 7/14 (50) |
2008 | 75/243 (31) | 13/57 (23) | 29/77 (37) | 4/16 (25) |
Total | 512/1562 (33) | 88/347 (25) | 239/495 (48) | 70/143 (49) |
טבלה 3: Enterobacteriaceae – antimicrobial susceptibilities (%) 2001-2008. Breakdown by source of patient
- מקרא
- Amp-Ampicillin;
- Amk-Amikacin;
- Aug-Amoxycillin-clavulanate,
- Carbap-Carbapenems;
- Caz-Ceftazidime;
- Cef-Cefazolin;
- Chl-Chloramphenicol;
- Cip-Ciprofloxacin;
- Col-colistin (polymyxin-B);
- Cpm,-Cefepime,
- Cro-Ceftriaxone;
- Cxm-Cefuroxime;
- Ert-Ertapenem (since 2005);
- Gen-Gentamicin;
- Imp-Imipenem;
- Mez-Mezlocillin (up to mid-2006);
- Meth-Methicillin; Sep-Cotrimoxazole;
- Tob-Tobramycin;
- Tzp-Piperacillin-Tazobactam;
- Van-Vancomycin.
Group | n | Penicillins | Carbap.[6] | Cephalosporins | Aminogly. | Other | |||||||||||
Aug | Mez | Tzp | Ert | Imp | Cef | Cxm | Cro | Caz | Cpm | Gen | Amk | Chl | Sep | Cip | Col | ||
≤48hr | 3447 | 66 | 49 | 91 | 99 | 99 | 61 | 75 | 83 | 85 | 85 | 83 | 97 | 79 | 62 | 73 | 86 |
>48hr | 1898 | 39 | 42 | 76 | 92 | 98 | 32 | 47 | 60 | 62 | 67 | 66 | 89 | 58 | 52 | 59 | 78 |
הערות שוליים
- ↑ 1.0 1.1 Data for 1990-2000 were manually computerized by volunteers from microbiology records; data for 2001-2008 were obtained with the cubes computer program.
- ↑ BC, blood cultures
- ↑ NA, not available
- ↑ Trend statistical analysis demonstrated an absence of significant changes in annual incidence of any of these organisms for 1990-2000.
- ↑ * Routine testing for ESBL was initiated in 2002
- ↑ Susceptibilities of Imipenem (Imp) and Meropenem (Mer) are not identical, but similar. Since 2006, the microbiology laboratory determines susceptibility to both imipenem and meropenem
ביבליוגרפיה
- לטבלה 1
- Yinnon AM, Schlesinger Y, Gabbay D, Rudensky B. Analysis of 5 years of bacteraemias: importance of stratification of microbial susceptibilities by source of patients. J Infect 1007 Jul; 35(1):17-23.
- Raveh D, Rudensky B, Schlesinger Y, Benenson S, Yinnon AM. Susceptibility trends in bacteraemias: Analysis of 7544 patient-unique bacteraemic episodes spanning 11 years (1990-2000). J Hosp Infect 2003.
- לטבלה 2
- Friedmann R, Raveh D, Zartzer E, Rudensky B, Broide E, Attias D, Yinnon AM. Prospective evaluation of colonization with extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing enterobacteriaceae among patients during hospitalization. Infect Control Hosp Epidemiol. 2009;30(6):534-42.
- Raveh D, Yinnon AM, Broide E, Rudensky B. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid. Chemotherapy. 2007;53(3):185-9.
- Cohen MJ, Anshelevich O, Raveh D, Broide E, Rudensky B, Yinnon AM. Acquisition of multidrug-resistant organisms among hospital patients hospitalized in beds adjacent to critically ill patients. Infect Control Hosp Epidemiol. 2006;27(7):675-81.
- Henshke-Bar-Meir R, Yinnon AM, Rudensky B, Attias D, Schlesinger Y, Raveh D. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae. Infection. 2006;34(2):66-74.
- Tallis E, Rudensky B, Attias D, Raveh D, Schlesinger Y, Yinnon AM. In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus. Diagn Microbiol Infect Dis. 1999;35(2):121-6